SCHEMBL22609096

SCHEMBL22609096

Clc1ccc2c(c1)C1(c3ccccc3-c3ccccc31)c1cccnc1-2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK2 Q15119 7/20 0.44
▸ KMT2A Q03164 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ AKR1A1 P14550 1/20 0.40
▸ AKR1B1 P15121 1/20 0.40
▸ HRH1 P35367 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ADRB2 P07550 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM4 P08173 1/20 0.39
▸ ABCB1 P08183 1/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ CHRM5 P08912 1/20 0.39
▸ ADRA2A P08913 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ ADRA2B P18089 1/20 0.39
▸ ADRA2C P18825 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29395626 1.00 PDK2 (0.44) PDK2KMT2ACYP1A2CYP2C19AKR1A1
SCHEMBL20089623 0.89 PDK2 (0.45) PDK2KMT2ACYP1A2CYP2C19AKR1A1
SCHEMBL11990868 0.85 PDK2 (0.56) PDK2KMT2ACYP1A2CYP2C19LMNA
SCHEMBL30322608 0.85 PDK2 (0.56) PDK2KMT2ACYP1A2CYP2C19LMNA
SCHEMBL19147675 0.83 PDK2 (0.58) PDK2KMT2AAKR1A1AKR1B1LMNA
SCHEMBL14099222 0.82 PDK2 (0.44) PDK2KMT2ACYP1A2CYP2C19LMNA
SCHEMBL16547417 0.82 PDK2 (0.44) PDK2KMT2ACYP1A2CYP2C19LMNA
SCHEMBL17816711 0.82 PDK2 (0.56) PDK2KMT2AAKR1A1AKR1B1LMNA
SCHEMBL32682807 0.80 PDK2 (0.49) PDK2KMT2ACYP1A2CYP2C19LMNA
SCHEMBL5344736 0.80 PDK2 (0.49) PDK2KMT2ACYP1A2CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220231234-A1 Compounds comprising a hetero-fluorene group NOVALED GMBH (DE) 2022-07-21 — — US disclosed
WO-2020221570-A1 COMPOUNDS COMPRISING A HETERO-FLUORENE GROUP NOVALED GMBH (DE) 2020-11-05 — — WO disclosed
EP-3733649-A1 HETERO-FLUORENE DERIVATIVES AND THEIR USE IN ELECTRONIC DEVICES Novaled GmbH (DE) 2020-11-04 — — EP disclosed
EP-3733649-A1 HETERO-FLUORENE DERIVATIVES AND THEIR USE IN ELECTRONIC DEVICES Novaled GmbH (DE) 2020-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220231234-A1 Compounds comprising a hetero-fluorene group AFF2, AFF1, AFF4 PDK2 3893/4885KMT2A 1349/4885CYP1A2 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback